BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

906 related articles for article (PubMed ID: 28918104)

  • 1. Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Katoh D; Ochi Y; Yabushita T; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Kaji S; Imai Y; Ishikawa T
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e91-e97. PubMed ID: 28918104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.
    Rambaldi A; Boschini C; Gritti G; Delaini F; Oldani E; Rossi A; Barbui AM; Caracciolo D; Ladetto M; Gueli A; De Crescenzo A; Passera R; Devizzi L; Patti C; Gianni AM; Tarella C
    Am J Hematol; 2013 Dec; 88(12):1062-7. PubMed ID: 23940056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
    Watanabe R; Tomita N; Itabashi M; Ishibashi D; Yamamoto E; Koyama S; Miyashita K; Takahashi H; Nakajima Y; Hattori Y; Motohashi K; Takasaki H; Ohshima R; Hashimoto C; Yamazaki E; Fujimaki K; Sakai R; Fujisawa S; Motomura S; Ishigatsubo Y
    Eur J Haematol; 2014 Mar; 92(3):204-10. PubMed ID: 24283206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.
    Sun F; Zhu J; Lu S; Zhen Z; Wang J; Huang J; Ding Z; Zeng M; Sun X
    BMC Cancer; 2018 Jan; 18(1):5. PubMed ID: 29291712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
    Yamamoto M; Watanabe K; Fukuda T; Miura O
    Anticancer Res; 2017 May; 37(5):2655-2662. PubMed ID: 28476841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 8. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.
    Li ZM; Huang JJ; Xia Y; Sun J; Huang Y; Wang Y; Zhu YJ; Li YJ; Zhao W; Wei WX; Lin TY; Huang HQ; Jiang WQ
    PLoS One; 2012; 7(7):e41658. PubMed ID: 22911837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
    Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era.
    Ho CL; Lu CS; Chen JH; Chen YG; Huang TC; Wu YY
    Medicine (Baltimore); 2015 Jun; 94(24):e993. PubMed ID: 26091479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
    Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.
    Keane C; Gill D; Vari F; Cross D; Griffiths L; Gandhi M
    Am J Hematol; 2013 Apr; 88(4):273-6. PubMed ID: 23460351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral blood lymphocyte to monocyte ratio recovery from low levels at diagnosis after completion of first line therapy predicts good clinical outcomes in patients with diffuse large B-cell lymphoma.
    Zhou S; Xu L; Ma Y; Tang L; Zhang Y; Shi Y; Sun L; Chen Y; Liang B; Zhou Y; Yu K; Shen J
    Oncotarget; 2017 Mar; 8(12):19556-19565. PubMed ID: 28107187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic model for relapsed/refractory transplant-ineligible diffuse large B-cell lymphoma utilizing the lymphocyte-to-monocyte ratio.
    Ide D; Fujino T; Kobayashi T; Egashira A; Miyashita A; Mizuhara K; Isa R; Tsukamoto T; Mizutani S; Uchiyama H; Kaneko H; Uoshima N; Kawata E; Taniwaki M; Shimura Y; Kuroda J
    Int J Hematol; 2024 Jun; 119(6):697-706. PubMed ID: 38492199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
    Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW
    Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
    Suzuki T; Maruyama D; Miyagi-Maeshima A; Nomoto J; Tajima K; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Taniguchi H; Izutsu K; Kobayashi Y; Tobinai K
    Cancer Med; 2021 Aug; 10(15):5101-5109. PubMed ID: 34105893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone.
    Chae YS; Shin H; Sohn SK; Lee SJ; Moon JH; Kang BW; Kim JG; Yang DH; Lee JJ; Park TI
    Leuk Lymphoma; 2012 Sep; 53(9):1757-63. PubMed ID: 22372848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO).
    Bento L; Díaz-López A; Barranco G; Martín-Moreno AM; Baile M; Martín A; Sancho JM; García O; Rodríguez M; Sánchez-Pina JM; Novelli S; Salar A; Bastos M; Rodríguez-Salazar MJ; González de Villambrosia S; Córdoba R; García-Recio M; Martínez-Serra J; Del Campo R; Luzardo H; García D; Hong A; Abrisqueta P; Sastre-Serra J; Roca P; Rodríguez J; Gutiérrez A;
    Br J Haematol; 2020 Mar; 188(6):888-897. PubMed ID: 31782146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma.
    Wei X; Huang F; Wei Y; Jing H; Xie M; Hao X; Feng R
    Leuk Res; 2014 Jun; 38(6):694-8. PubMed ID: 24713260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
    Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
    Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.